How Much Does Semaglutide Cost? (2026)

Few drugs in the weight-management space provoke more price confusion than semaglutide. The same active molecule is sold under three different brand names, priced for different indications, and also available through compounding pharmacies at a fraction of the retail cost — all while the FDA has significantly tightened the rules around that lower-cost compounding pathway since 2025. Understanding what you'll actually pay requires knowing which version is being prescribed, who's paying for it, and whether the legal landscape in 2026 still permits the cheaper route you may have read about.

This guide covers every pricing tier, the regulatory changes that reshaped access in the past 18 months, the total cost of a supervised program, and the questions worth asking before committing to any payment path.

What semaglutide is and why it has multiple prices

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — a synthetic peptide hormone that mimics the body's own GLP-1 signaling. It is sold under three FDA-approved brand names by Novo Nordisk, each approved for different indications and available at different doses:

• Wegovy — approved for chronic weight management. Weekly subcutaneous injection, doses up to 2.4 mg. List price: $1,349 per month at retail.
• Ozempic — approved for type 2 diabetes management and to reduce cardiovascular risk in adults with established heart disease. Weekly subcutaneous injection, doses up to 2 mg. List price: $998 per month at retail.
• Rybelsus — approved for type 2 diabetes. Daily oral tablet. List price: $936 per month at retail.
• Oral Wegovy — oral semaglutide approved for weight management, launched January 2026. Starting at $149 per month for the low introductory dose; higher maintenance doses cost more.

The pricing difference between Ozempic and Wegovy is not a difference in the drug. It is a difference in the approved indication, the maximum dose, and crucially, how insurers treat each. A patient on Ozempic for diabetes and a patient on Wegovy for weight management may both be injecting semaglutide weekly, but their insurance coverage, copays, and total out-of-pocket costs can differ by more than $1,000 per month.

Semaglutide price comparison by access path

Access path	Monthly cost	Prescription required	Insurance applies	Notes
Brand Wegovy — retail list price	$1,349	Yes	If covered	Most plans require prior auth; many exclude weight-loss indication
Brand Ozempic — retail list price	$998	Yes	If covered	More commonly covered for type 2 diabetes diagnosis
Rybelsus (daily oral tablet, diabetes)	$936	Yes	If covered	Lower bioavailability than injectable forms
Oral Wegovy (weight management pill)	From $149	Yes	If covered	Starting dose only; maintenance dose pricing higher
NovoCare Pharmacy — self-pay direct (Wegovy ≤2.4 mg or Ozempic ≤1 mg)	$349	Yes	No (self-pay only)	Not available to Medicare/Medicaid; ships direct to patient
NovoCare Pharmacy — self-pay direct (Ozempic 2 mg)	$499	Yes	No (self-pay only)	Not available to Medicare/Medicaid
Commercial insurance + Novo savings card	~$25	Yes	Yes (required)	Card has eligibility limits; plan must cover the drug first
Medicare Part D — GLP-1 Bridge Program (Wegovy)	$50	Yes	Yes (Part D)	Bridge Program launched July 1, 2026; eligibility and PA required
Compounded semaglutide — telehealth (patient-specific, 503A)	$69–$249	Yes	No	Mass compounding ended 2025; verify pharmacy compliance

The brand-name pricing tiers explained

Retail list price: the number most people won't pay

Wegovy's $1,349 and Ozempic's $998 monthly retail list prices are the prices you'd pay at a retail pharmacy without any insurance coverage, discount program, or manufacturer savings program. GoodRx pricing at major chain pharmacies tracks close to list price for GLP-1 drugs — unlike generics, where GoodRx coupons produce large discounts, there is no generic semaglutide and no competing biosimilar as of 2026. Novo Nordisk's patents extend through approximately 2031. The list price is the practical ceiling; it's also the price most people see first and find alarming enough to start searching for alternatives.⁴

NovoCare Pharmacy: the manufacturer's own $349 direct path

In March 2025, Novo Nordisk launched NovoCare Pharmacy, a manufacturer-direct dispensing channel that ships Wegovy, Ozempic, and Rybelsus directly to patients' homes or to CVS retail locations. The self-pay pricing available through NovoCare is substantially lower than retail list prices because Novo Nordisk bypasses the standard pharmacy distribution chain.

As of mid-2026, the standard NovoCare self-pay prices are:

• Wegovy injectable (all doses through 2.4 mg): $349 per month
• Ozempic injectable (doses through 1 mg): $349 per month
• Ozempic injectable (2 mg maintenance dose): $499 per month
• Oral semaglutide tablets (oral Wegovy, 1.5 mg and 4 mg doses): $149 per month

The NovoCare pathway requires a valid prescription from a licensed U.S. provider. It is not available to Medicare, Medicaid, TRICARE, or VA beneficiaries, who are excluded by federal anti-kickback statute.⁵ For uninsured or commercially insured patients who don't have plan coverage, NovoCare represents the cheapest brand-name semaglutide available without going through the compounded market.

With commercial insurance: the savings card path to ~$25/month

Patients with commercial insurance plans that cover Wegovy or Ozempic can activate a Novo Nordisk savings card that brings the monthly copay to approximately $25 for eligible patients. The catch is the coverage itself: most plans require prior authorization, and the documentation requirements differ significantly depending on whether the indication is diabetes or weight management.

Plans that cover Ozempic for diabetes are generally more straightforward to authorize than plans that cover Wegovy for weight management, because obesity coverage restrictions remain more common than diabetes coverage restrictions in commercial insurance. A prescriber who documents a type 2 diabetes diagnosis and orders Ozempic faces a more routine prior authorization process than one ordering Wegovy for a patient whose primary diagnosis is obesity without a comorbidity. The savings card reduces cost substantially once coverage is confirmed; the prior authorization process is the gate that determines whether coverage exists at all.

Medicare: $50/month under the 2026 Bridge Program

Medicare Part D historically covered Ozempic for type 2 diabetes but excluded GLP-1 drugs used solely for weight management. In July 2026, the Medicare GLP-1 Bridge Program launched, making Wegovy available to eligible Part D enrollees at a $50 monthly copay. This is the single most significant access change in the semaglutide market this year. Eligibility requires both Part D enrollment and prior authorization through the enrollee's specific plan; the Bridge Program is not automatic. Medicare beneficiaries cannot use NovoCare self-pay pricing or manufacturer savings cards, which are barred by federal anti-kickback law.

Compounded semaglutide: what it costs and what changed in 2025

The compounded semaglutide market operated under unusually broad permission from 2022 through early 2025 because Ozempic and Wegovy were on the FDA's official drug shortage list. That shortage designation allowed licensed pharmacies to legally compound essentially-a-copy semaglutide products — something normally prohibited — as a workaround to supply constraints. The economics were straightforward: telehealth providers partnered with compounding pharmacies to offer the same active molecule at $69 to $249 per month, roughly one-fifth to one-fourteenth of Wegovy's retail list price.

That broad permission ended formally on February 21, 2025, when the FDA issued a determination that the semaglutide shortage was resolved.¹ The FDA set staggered wind-down deadlines: 503A pharmacies (state-licensed, traditional compounders) had 60 days — until April 22, 2025 — to cease mass compounding. FDA-registered 503B outsourcing facilities had 90 days, until May 22, 2025.

As the FDA's determination stated: "FDA has confirmed with the drug's manufacturer that their stated product availability and manufacturing capacity can meet the present and projected national demand." Once the shortage ended, the legal basis for mass compounding of an essentially-a-copy product was removed.

In 2026, compounded semaglutide remains legal, but only in a narrower lane:

• 503A pharmacies (state-licensed) can still fill individual patient prescriptions when a licensed physician documents a clinical need the brand product cannot address — such as a documented allergy to an inactive ingredient in the brand formulation, or a required dose or concentration not commercially available.
• 503B outsourcing facilities (FDA-registered, federal CGMP standards) may compound for specific patients or office use when they meet the applicable conditions.
• Mass-produced, non-patient-specific compounded semaglutide is no longer permitted under current FDA enforcement policy.

In practice, many telehealth platforms have remained active by documenting patient-specific clinical justifications under 503A rules. The compounded price range of $69 to $249 per month has largely held since the shortage ended, with a median tracked price of approximately $141 per month across providers as of September 2026.³ However, the legal and regulatory environment for compounded semaglutide is more contested than it was in 2024, and the terms of individual telehealth programs vary. Patients should confirm in writing which pharmacy their provider uses and verify that pharmacy's current operating status.

The FDA safety concern with compounded semaglutide

The FDA's alert from July 2024 documented a specific risk pattern with compounded injectable semaglutide that is worth understanding before evaluating cost tradeoffs. The FDA received reports of adverse events — some requiring hospitalization — linked to dosing errors with compounded semaglutide vials.²

As the FDA described: "Dosing errors have resulted from patients measuring and self-administering incorrect doses of the drug and health care providers miscalculating doses of the drug." The agency documented cases where patients administered 5 to 20 times more than the intended dose. Brand-name Ozempic and Wegovy are dispensed in pre-filled pens with preset doses; compounded versions come in multi-dose vials that require the patient to draw up the correct volume with a syringe — an unfamiliar task for most patients.

The FDA also flagged that some compounders use salt forms of semaglutide — semaglutide sodium or semaglutide acetate — rather than the base form used in the approved drugs. The FDA has stated it is "not aware of any basis" for compounding with salt forms that would meet the relevant legal conditions, and the safety and efficacy of the salt forms have not been established in clinical trials.

What drives the price differences

Regulatory pathway and manufacturing standards

FDA-approved drugs undergo years of clinical trials, manufacturing inspections, and quality reviews before reaching patients. Brand-name semaglutide products are manufactured under strict pharmaceutical-grade conditions with validated dosing delivery systems — the pre-filled pen format that makes dosing straightforward and reduces human error. Compounded versions are prepared by individual pharmacies on a prescription-by-prescription basis and do not go through FDA pre-market review. The lower price of compounded semaglutide reflects the absence of those costs; it also reflects the absence of those safeguards.

Indication and insurance dynamics

Ozempic's lower retail price relative to Wegovy reflects its diabetes approval, not any difference in the molecule. Insurers have historically been more willing to cover and authorize diabetes drugs than weight-loss drugs, so Ozempic's total cost to patients with commercial insurance is often lower than Wegovy's even before accounting for list price. The 2026 Medicare Bridge Program narrows this gap for Medicare patients, but commercial insurance formulary placement still differs significantly across plans for the two drugs.

The clinical trial data underpinning brand-name semaglutide's price

Novo Nordisk's Wegovy pricing incorporates the cost of the STEP clinical trial program, which produced the efficacy data that earned FDA approval for weight management. The STEP-1 trial, published in the New England Journal of Medicine in 2021, found that once-weekly semaglutide 2.4 mg produced a mean weight reduction of approximately 14.9% over 68 weeks in adults with overweight or obesity, compared to 2.4% with placebo — a difference the authors characterized as clinically meaningful.⁶ That trial data is the regulatory foundation for Wegovy's approval and the primary clinical basis for insurers' coverage decisions. No equivalent large-scale randomized trial has evaluated compounded semaglutide products; their clinical assumptions are borrowed from the brand-name evidence base.

Hidden costs and the real total of a supervised program

Patients comparing access paths frequently underestimate total cost because advertised prices often represent only part of what they'll actually pay. A realistic accounting:

Brand-name pathway (with commercial insurance)

• Prior authorization processing: Typically no direct cost to the patient, but requires physician time and documentation; delays of 2 to 4 weeks are common
• Copay after coverage approval: $25 per month with the savings card for eligible patients; $0 after hitting the Part D out-of-pocket cap for Medicare patients; variable without a savings card
• Physician visits: Initial evaluation and follow-up visits depend on your plan's cost-sharing; telehealth visits through GLP-1 platforms typically run $75–$150 each

NovoCare self-pay pathway (no insurance)

• Prescription visit: $75–$200 for an initial telehealth evaluation if not already under a physician's care
• Monthly medication cost: $349 (Wegovy or Ozempic ≤1 mg); $499 (Ozempic 2 mg)
• Supplies: NovoCare ships brand pre-filled pens; no separate syringe cost, though alcohol wipes and sharps disposal containers add a small monthly cost
• Realistic annual total: $4,300–$6,100 depending on dose, physician visit frequency, and labs

Compounded telehealth pathway

• Consultation fee: $0–$150 depending on the platform; some bundle it into the monthly subscription price
• Monthly medication cost: $69–$249; starting dose pricing is often lower than maintenance dose pricing at the same platform
• Injection supplies: Syringes, alcohol swabs, and bacteriostatic water add $15–$30 per month; multi-dose vials require drawing up each dose yourself
• Dose escalation pricing: Many platforms that advertise $69–$99 starting prices charge $149–$249 at therapeutic maintenance doses; ask for the full dose-escalation price schedule before committing
• Realistic annual total: $1,000–$3,500 depending on dose, provider, and consultation model

The compounded pathway is consistently cheaper. Whether it represents better value depends on how much weight you give to the pre-filled pen delivery format, the absence of FDA review for the compounded product, and the current legal complexity around patient-specific justification requirements.

Insurance, HSAs, and Medicare in detail

Insurance coverage for semaglutide is the most consequential single variable in total cost. The framework differs significantly by coverage type:

• Commercial insurance (employer-sponsored or marketplace): Covers Ozempic more consistently for type 2 diabetes than Wegovy for weight management. Prior authorization is standard; medical necessity documentation is required. The Novo savings card applies only to commercially insured patients and does not work for government insurance beneficiaries.
• Medicare Part D: Covered Ozempic for diabetes before 2026; the GLP-1 Bridge Program now extends coverage to Wegovy for eligible enrollees at $50/month. The $2,100 annual Part D out-of-pocket cap applies across all Part D drugs, so patients with multiple medications may reach $0 cost partway through the year. Manufacturer savings cards are barred for Medicare patients.
• HSA/FSA: May cover semaglutide costs when prescribed by a licensed physician for a qualifying condition. Confirm with your account administrator before assuming eligibility, as rules vary by plan year and condition.
• Medicaid: Coverage varies by state; contact your state Medicaid office for current formulary status.

The FDA's Inflation Reduction Act drug price negotiation process selected semaglutide (Ozempic, Wegovy, Rybelsus) for the second negotiation round, with a negotiated Maximum Fair Price scheduled to take effect January 1, 2027. That will create a federally capped Medicare rate; 2026 remains under the standard Part D structure.

Semaglutide in context: how it compares to other peptide weight-loss approaches

Semaglutide is frequently discussed alongside other weight-loss peptides, but it occupies a different regulatory category than research peptides like sermorelin or tesamorelin. Semaglutide has FDA approval with a defined efficacy and safety profile established in large controlled trials. Research peptides used for weight loss operate without that evidentiary infrastructure. For a full comparison of semaglutide against other approaches, including peptides without FDA approval, our peptides vs. Ozempic comparison covers the relevant distinctions. For general context on the peptide drug category and how semaglutide fits into it, that foundational guide is the right starting point.

Among GLP-1 class drugs, tirzepatide (Zepbound, Mounjaro) — which targets both GLP-1 and GIP receptors — has shown higher average weight loss in trials than semaglutide and also has a compounded market. Compounded tirzepatide generally costs more than compounded semaglutide (roughly $119–$299 per month versus $69–$249), so semaglutide remains the lower-cost entry point into this class of medication.

Questions to ask before committing to any semaglutide program

• Which pharmacy dispenses it, and can you verify their license? For compounded semaglutide, the dispensing pharmacy should be either an FDA-registered 503B outsourcing facility (verifiable on the FDA website) or a state-licensed 503A pharmacy (verifiable through the relevant state pharmacy board). Ask for the pharmacy name before enrolling.
• Does your provider use semaglutide base or a salt form? Semaglutide sodium and semaglutide acetate are different substances from the base form used in FDA-approved products. The FDA has expressed concern about compounders using salt forms. Ask explicitly which form is being dispensed.
• What is the full dose-escalation price schedule? Starting dose prices are often lower than maintenance dose prices. Get the complete pricing at every step of your titration protocol before you commit.
• What is included in the monthly subscription fee? Consultations, follow-up visits, lab orders, and supplies are sometimes bundled and sometimes billed separately. Get an itemized breakdown.
• What are the cancellation and refund terms? Prepaid multi-month plans typically carry no-refund policies once the medication has shipped. Understand the commitment before paying.
• Is your prescriber documenting a patient-specific clinical justification for the compounded version? Post-shortage rules require this documentation. Without it, the prescription may not be legally dispensable by the pharmacy.

What this page cannot tell you

This guide covers pricing. It cannot tell you whether semaglutide is clinically appropriate for your situation, what dose is right, or whether the evidence supports its use for your specific health goals. Those questions require a conversation with a licensed physician. The regulatory landscape around compounded semaglutide has changed repeatedly since 2023 and may change again; verify the current status with your prescriber and pharmacy at the time of your prescription, not based on information in any guide including this one.

For context on how the licensed telehealth and compounding pathways compare across all peptide-class drugs — not just semaglutide — our guide to telehealth vs. research vendors covers the full tradeoff. For guidance on how to navigate any supervised peptide or prescription protocol safely, how to try peptides safely covers the principles that apply across this entire drug class.